NCT02640209 · Interventional trial
Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Overall registry status Terminated
Early Phase 1
Conditions LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Delaware Valley sites
- Abramson Cancer Center of the University of Pennsylvania · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory